Human CTLA-4, C-His Tag Protein

RMB: 599 特惠 1619 1619

产品规格

20μg

50μg

100μg

现在订购，【现货】

点击询价

联系我们

邮箱: sales@huabio.cn

电话: 0571-88062880

查找各地代理商

Catalog# HA210885

Human CTLA-4, C-His Tag Protein

Product Information

Product name

Human CTLA-4, C-His Tag Protein

Catalog No.

HA210885

Predicted molecular mass

14.9 kD

Protein construction description

A DNA sequence encoding the human CTLA-4 protein (P16410) (Lys 36-Asp 161) was expressed with a His tag at the C-terminus

Accession

P16410

Protein construction

His CTLA-4 (36-161) His

Source

HEK293

Bio Activity

Testing in progress.

Purity

>95% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Formulation

Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, 5% Trehalose, 5% mannitol.

Species

Human

Background

CTLA-4 or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. Variants in this gene have been associated with Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, primary biliary cirrhosis and other autoimmune diseases. Polymorphisms of the CTLA-4 gene are associated with autoimmune diseases such as rheumatoid arthritis, autoimmune thyroid disease and multiple sclerosis, though this association is often weak. In systemic lupus erythematosus (SLE), the splice variant sCTLA-4 is found to be aberrantly produced and found in the serum of patients with active SLE. Germline haploinsufficiency of CTLA-4 leads to CTLA-4 deficiency or CHAI disease (CTLA4 haploinsufficiency with autoimmune infiltration), a rare genetic disorder of the immune system. Symptomatic patients with CTLA-4 mutations are characterized by an immune dysregulation syndrome including extensive T cell infiltration in a number of organs, including the gut, lungs, bone marrow, central nervous system. Once a diagnosis is made, the treatment is based on an individual’s clinical condition and may include standard management for autoimmunity and immunoglobulin deficiencies. The comparatively higher binding affinity of CTLA-4 than CD28 has made it a potential therapy for autoimmune diseases.

Usage guide

Shipping

In general, recombinant proteins are provided as lyophilized powder which are shipped with blue ice. Bulk packages of recombinant proteins are provided as frozen liquid which are shipped with dry ice.

Storage

Please avoid repeated freeze-thaw cycles. Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ It is recommended that aliquot the reconstituted solution to minimize freeze-thaw cycles.